Christoph Engel1, Hans F Vasen2, Toni Seppälä3, Stefan Aretz4, Marloes Bigirwamungu-Bargeman5, Sybrand Y de Boer6, Karolin Bucksch7, Reinhard Büttner8, Elke Holinski-Feder9, Stefanie Holzapfel4, Robert Hüneburg10, Maarten A J M Jacobs11, Heikki Järvinen3, Matthias Kloor12, Magnus von Knebel Doeberitz12, Jan J Koornstra13, Mariette van Kouwen14, Alexandra M Langers2, Paul C van de Meeberg6, Monika Morak9, Gabriela Möslein15, Fokko M Nagengast14, Kirsi Pylvänäinen16, Nils Rahner17, Laura Renkonen-Sinisalo3, Silvia Sanduleanu18, Hans K Schackert19, Wolff Schmiegel20, Karsten Schulmann21, Verena Steinke-Lange9, Christian P Strassburg10, Juda Vecht22, Marie-Louise Verhulst23, Wouter de Vos Tot Nederveen Cappel22, Silke Zachariae7, Jukka-Pekka Mecklin24, Markus Loeffler7. 1. Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. Electronic address: christoph.engel@imise.uni-leipzig.de. 2. Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands. 3. Department of Abdominal Surgery, Helsinki University Hospital, Helsinki, Finland. 4. Institute of Human Genetics, University of Bonn, Bonn, Germany; Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany. 5. Department of Gastroenterology and Hepatology, Medisch Spectrum Hospital, Enschede, The Netherlands. 6. Department of Gastroenterology and Hepatology, Slingeland Hospital, Doetinchem, The Netherlands. 7. Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. 8. Institute of Pathology, University of Cologne, Cologne, Germany. 9. Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany; Center of Medical Genetics, Munich, Germany. 10. Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany. 11. Department of Gastroenterology and Hepatology, Free University Medical Centre, Amsterdam, The Netherlands. 12. Department of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Cooperation Unit Applied Tumour Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 13. Department of Gastroenterology and Hepatology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. 14. Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands. 15. Center for Hereditary Tumors, HELIOS Klinikum Wuppertal, University Witten-Herdecke, Wuppertal, Germany. 16. Department of Education and Research, Jyväskylä Central Hospital, Jyväskylä, Finland. 17. Institute of Human Genetics, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany. 18. Department of Gastroenterology and Hepatology, University Medical Centre Maastricht, Maastricht, The Netherlands. 19. Department of Surgical Research, Technische Universität Dresden, Dresden, Germany. 20. Department of Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany. 21. Department of Internal Medicine, Hematology and Oncology, Klinikum Arnsberg, Arnsberg, Germany. 22. Department of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands. 23. Department of Gastroenterology and Hepatology, Maxima Medical Centre, Eindhoven, The Netherlands. 24. Departments of Education and Research and Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland; Sports and Health Sciences, Jyväskylä University, Jyväskylä, Finland.
Abstract
BACKGROUND & AIMS: Patients with Lynch syndrome are at high risk for developing colorectal cancer (CRC). Regular colonoscopic surveillance is recommended, but there is no international consensus on the appropriate interval. We investigated whether shorter intervals are associated with lower CRC incidence and detection at earlier stages by comparing the surveillance policies in Germany, which evaluates patients by colonoscopy annually, in the Netherlands (patients evaluated at 1-2-year intervals), and Finland (patients evaluated at 2-3-year intervals). METHODS: We collected data from 16,327 colonoscopic examinations (conducted from 1984 through 2015) of 2747 patients with Lynch syndrome (pathogenic variants in the MLH1, MSH2, or MSH6 genes) from the German HNPCC Consortium, the Dutch Lynch Syndrome Registry, and the Finnish Lynch Syndrome Registry. Our analysis included 23,309 person-years of cumulative observation time. Time from the index colonoscopy to incident CRC or adenoma was analyzed using the Kaplan-Meier method; groups were compared using the log-rank test. We performed multivariable Cox regression analyses to identify factors associated with CRC risk (diagnosis of CRC before the index colonoscopy, sex, mutation, age, and presence of adenoma at the index colonoscopy). RESULTS: The 10-year cumulative CRC incidence ranged from 4.1% to 18.4% in patients with low- and high-risk profiles, respectively, and varied with age, sex, mutation, and prior detection of CRC or adenoma. Observed colonoscopy intervals were largely in accordance with the country-specific recommendations. We found no significant differences in cumulative CRC incidence or CRC stage at detection among countries. There was no significant association between CRC stage and time since last colonoscopy. CONCLUSIONS: We did not find a significant reduction in CRC incidence or stage of detection in Germany (annual colonoscopic surveillance) than in countries with longer surveillance intervals (the Netherlands, with 1-2-year intervals, and Finland, with 2-3-year intervals). Overall, we did not find a significant association of the interval with CRC risk, although age, sex, mutation, and prior neoplasia were used to individually modify colonoscopy intervals. Studies are needed to develop and validate risk-adapted surveillance strategies and to identify patients who benefit from shorter surveillance intervals.
BACKGROUND & AIMS:Patients with Lynch syndrome are at high risk for developing colorectal cancer (CRC). Regular colonoscopic surveillance is recommended, but there is no international consensus on the appropriate interval. We investigated whether shorter intervals are associated with lower CRC incidence and detection at earlier stages by comparing the surveillance policies in Germany, which evaluates patients by colonoscopy annually, in the Netherlands (patients evaluated at 1-2-year intervals), and Finland (patients evaluated at 2-3-year intervals). METHODS: We collected data from 16,327 colonoscopic examinations (conducted from 1984 through 2015) of 2747 patients with Lynch syndrome (pathogenic variants in the MLH1, MSH2, or MSH6 genes) from the German HNPCC Consortium, the Dutch Lynch Syndrome Registry, and the Finnish Lynch Syndrome Registry. Our analysis included 23,309 person-years of cumulative observation time. Time from the index colonoscopy to incident CRC or adenoma was analyzed using the Kaplan-Meier method; groups were compared using the log-rank test. We performed multivariable Cox regression analyses to identify factors associated with CRC risk (diagnosis of CRC before the index colonoscopy, sex, mutation, age, and presence of adenoma at the index colonoscopy). RESULTS: The 10-year cumulative CRC incidence ranged from 4.1% to 18.4% in patients with low- and high-risk profiles, respectively, and varied with age, sex, mutation, and prior detection of CRC or adenoma. Observed colonoscopy intervals were largely in accordance with the country-specific recommendations. We found no significant differences in cumulative CRC incidence or CRC stage at detection among countries. There was no significant association between CRC stage and time since last colonoscopy. CONCLUSIONS: We did not find a significant reduction in CRC incidence or stage of detection in Germany (annual colonoscopic surveillance) than in countries with longer surveillance intervals (the Netherlands, with 1-2-year intervals, and Finland, with 2-3-year intervals). Overall, we did not find a significant association of the interval with CRC risk, although age, sex, mutation, and prior neoplasia were used to individually modify colonoscopy intervals. Studies are needed to develop and validate risk-adapted surveillance strategies and to identify patients who benefit from shorter surveillance intervals.
Authors: Elisabeth F P Peterse; Steffie K Naber; Corinne Daly; Aaron Pollett; Lawrence F Paszat; Manon C W Spaander; Melyssa Aronson; Robert Gryfe; Linda Rabeneck; Iris Lansdorp-Vogelaar; Nancy N Baxter Journal: Clin Gastroenterol Hepatol Date: 2019-10-17 Impact factor: 11.382
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: Felipe F Quezada-Diaz; Irbaz Hameed; Alexa von Mueffling; Erin E Salo-Mullen; Alice Catalano; J Joshua Smith; Martin R Weiser; Julio Garcia-Aguilar; Zsofia K Stadler; Jose G Guillem Journal: J Am Coll Surg Date: 2020-01-30 Impact factor: 6.532